The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease

Virology

Volumn 247, Issue 1, 1998, Pages 51-61

  Dunn, C S ^a   Samuel, A R ^a   Pullen, L A ^a   Anderson, J ^a  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOOT AND MOUTH DISEASE VACCINE;

ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GUINEA PIG; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; VIRUS VIRULENCE;

ANIMALIA; BOVINAE; CAVIA; CAVIA PORCELLUS; FOOT-AND-MOUTH DISEASE VIRUS; MURINAE; RNA VIRUSES; SUS SCROFA;

EID: 0032551596     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9175     Document Type: Article

References (72)

1. Abu Elzein E. M. E., Crowther J. R. Enzyme-labelled immunosorbent assay techniques in foot-and-mouth disease virus research. J. Hygiene. 80:1978;391-399.
2. Acharya R., Fry E., Stuart D., Fox G., Rowlands D., Brown F. The three-dimensional structure of foot-and-mouth disease virus at 2.9A resolution. Nature. 337:1989;709-716.
3. Anonymous. OIE Disease Infor. 10:1997;53.
4. Bahnemann H. G. Binary ethlyenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch. Virol. 47:1975;47-56.
5. Bahnemann H. G. Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine. 8:1990;299-303.
6. Balachandran N., Bacchetti S., Rawls W. E. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect. Immun. 37:1982;1132-1137.
7. Bartels T., Schafer H., Liebermann H., Burger R., Beyer J. T-lymphocyte responses in guinea pigs vaccinated with foot-and-mouth disease vaccine. Vet. Immuno. Immunopathol. 40:1994;213-223.
8. Boere W. A. M., Benaissa-Trouw B. J., Harmsen T., Erich T., Kraaijeveld C. A., Snippe H. Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus. J. Virol. 54:1985;546-551.
9. Borrego B., Camarero J. A., Mateu M. G., Domingo E. A highly divergent antigenic site of foot-and-mouth disease virus retains its immunodominance. Viral Immunol. 8:1995;11-19.
10. Brown F. New approaches to vaccination against foot-and-mouth disease. Vaccine. 10:1992;1022-1026.
11. Cecilia D., Gould E. A. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralisation-resistant mutants. Virology. 181:1991;70-77.
12. Crowther J. R., Farias S., Carpenter W. C., Samuel A. R. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterisation of single and quintuple monoclonal antibody escape mutants. J. Gen. Virol. 74:1993;1547-1553.
13. Davidson F. L., Crowther J. R., Nqindi J., Knowles N. J., Thevasagayam S. J., van Vuuren C. J. Antigenic analysis of SAT-2 serotype foot-and-mouth disease virus isolates from Zimbabwe using monoclonal antibodies. Epidem. Inf. 115:1995;193-205.
14. Diamond D. C., Jameson B. A., Bonin J., Kohara M., Abe S., Itoh H., Komatsu T., Arita M., Kuge S., Nomoto A., Osterhaus A. D. M. E., Cranic R., Wimmer E. Antigenic variation and resistance to neutralization in poliovirus type 1. Science. 229:1985;1090-1093.
15. Di Girolamo W., Salas M., Laguens R. P. Role of Langerhans cells in the infection of the guinea pig epidermis with foot-and-mouth disease virus. Arch. Virol. 83:1985;331-336.
16. DiMarchi R., Brooke G., Gale C., Cracknell V., Doel T., Mowat N. Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science. 232:1986;639-641.
17. Doel T. R., Gale C., Do Amaral C. M. C. F., Mulcahy G., DiMarchi R. Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus. J. Virol. 64:1990;2260-2264.
18. Doel T. R., Williams L., Barnett P. V. Emergency vaccination against foot-and-mouth disease: Rate of development of immunity and its implications for the carrier state. Vaccine. 12:1994;592-600.
19. Dunn C. S., Donaldson A. I. Natural adaption to pigs of a Taiwanese isolate of foot-and-mouth disease virus. Vet Record. 141:1997;174-175.
20. Gould E. A., Buckley A., Barrett A. D. T., Cammack N. Neutralising (54K) and non-neutralising (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J. Gen. Virol. 67:1986;591-595.
21. Gould E. A., Buckley A., Cane P. A., Higgs S., Cammack N. Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild type antigenic variant in 17D vaccine pools. J. Gen. Virol. 70:1989;1889-1894.
22. Hamblin C., Kitching R. P., Donaldson A. I., Crowther J. R., Barnett I. T. R. Enzyme-linked immunosorbant assay (ELISA) for the detection of antibodies against foot-and-mouth disease virus. Epidemiol. Infect. 99:1987;733-744.
23. Hewat E. A., Verdaguer N., Fita I., Blakemore W., Brookes S., King A., Newman J., Domingo E., Mateu M. G., Stuart D. I. Structure of the complex of an Fab fragment of a neutralization antibody with foot-and-mouth disease virus: Positioning of a highly mobile antigenic loop. EMBO J. 16:1997;1492-1500.
24. Hogle J. M., Chow M., Filman D. J. Three-dimensional structure of poliovirus at 2.9A resolution. Science. 229:1985;1358-1365.
25. Holzmann H., Stiasny K., Ecker M., Kunz C., Heniz F. X. Characterization of monoclonal antibody-escape mutants of tick-bourne encephalitis virus with reduced neuroinvasiveness in mice. J. Gen. Virol. 78:1997;31-37.
26. Icenogle J. P., Minor P. D., Ferguson M., Hogle J. M. Modulation of humoral immune response to a 12-amino acid site on the poliovirus virion. J. Virol. 60:1986;297-301.
27. Johnson B. J., Brubaker J. R., Roehrig J. T., Trent D. W. Variants of Venezuelan equine encephalitis virus that resist neutralisation define a domain of the E2 glycoprotein. Virology. 177:1990;676-683.
28. Karber G. Beitrag zur kollektiven behandlung pharmakologischer Reihenversuche. Arch. Exp. Path. Pharm. 162:1931;480-483.
29. Kitching R. P., Rendle R., Ferris N. P. Rapid correlation between field isolates and vaccine strains of foot-and-mouth disease. Vaccine. 6:1988;403-408.
30. Kitching R. P., Knowles N. J., Samuel A. R., Donaldson A. I. Development of foot-and-mouth disease virus strain characterisation - A review. Trop. Anim. Health Prod. 21:1989;153-166.
31. Kitson J. D. A., McCahon D., Belsham G. J. Sequence analysis of monoclonal antibody resistant mutants of type O foot-and-mouth disease virus: Evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. Virology. 179:1990;26-34.
32. Knudsen R. C., Groocock C. M., Andersen A. A. Immunity to foot-and-mouth disease virus in guinea pigs: Clinical and immune responses. Infect. Immun. 24:1979;787-792.
33. Knudsen R. C., Groocock C. M., Andersen A. A. Difference in protective immunity of the tongue and feet of guinea pigs vaccinated with foot-and-mouth disease virus type A12 following intradermolingual and footpad challenge. Vet. Micro. 7:1982;97-107.
34. Knudsen R. C., Groocock C. M., Andersen A. A. Protective role of foot-and-mouth disease virus antibodyin vitroin vivo. J. Gen. Virol. 64:1983;341-348.
35. Kovamees J., Rydbeck R., Orvell C., Norrby E. Hemagglutinin-neuraminidase (HN) amino acid alterations in neutralisation escape mutants of Kilham mumps virus. Virus Res. 17:1990;119-130.
36. Kumel G., Kaerner H. C., Levine M., Schroder C. L., Glorioso J. Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity. J. Virol. 56:1985;930-937.
37. 1. Structure. 3:1995;571-580.
38. Lefrancois L. Protection against lethal viral infection by neutralizing and non-neutralizing monoclonal antibodies: distinct mechanisms of actionin vivo. J. Virol. 51:1984;208-214.
39. Mateu M. G. Antibody recognition of picornaviruses and escape from neutralisation: A structural view. Virus Res. 38:1995;1-24.
40. McCahon D., Crowther J. R., Belsham G. J., Kitson J. D. A., Duchesne M., Have P., Meloen R. H., Morgan D. O., De Simone F. Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants. J. Gen. Virol. 70:1989;639-645.
41. McCullough K. C., Crowther J. R., Butcher R. N., Carpenter W. C., Brocchi E., Capucci L., De Simone F. Immune protection against foot-and-mouth disease virus studied using virus-neutralizing and non-neutralizing concentrations of monoclonal antibodies. Immunology. 58:1986;421-428.
42. McCullough K. C., Smale C. J., Carpenter W. J., Crowther J. R., Brocchi E., De Simone F. Conformational alteration in foot-and-mouth disease virus virion capsid structure after complexing with monospecific antibody. Immunology. 60:1987;75-82.
43. McCullough K. C., Parkinson D., Crowther J. R. Opsonization-enhanced phagocytosis of foot-and-mouth disease virus. Immunology. 65:1988;187-191.
44. McCullough K. C., De Simone F., Brocchi E., Capucci L., Crowther J. R., Kihm L. Protective immune response against foot-and-mouth disease. J. Virol. 66:1992;1835-1840.
45. Minor P. D. Growth, assay and purification of picornaviruses. Virology, a Practical Approach. 1986;IRL Press, Oxford. p. 35-40.
46. Mulcahy G., Reid E., DiMarchi R. D., Gale C., Doel T. R. Maturation of functional antibody affinity in animals immunised with synthetic foot-and-mouth disease virus. Res. Vet. Sci. 52:1992;133-140.
47. Mulcahy G., Pullen L. A., Gale C., DiMarchi R. D., Doel T. R. Mouse protection test as a predictor of the protective capacity of synthetic foot-and-mouth disease vaccines. Vaccine. 9:1991;19-24.
48. Pay T. W. F., Hingley P. J. The use of serum neutralizing antibody assay for the determination of the potency of foot-and-mouth disease vaccines in cattle. Dev. Biol. Stand. 64:1986;153-161.
49. Pay T. W. F., Hingley P. J. Foot-and-mouth disease vaccine potency tests in cattle: The interrelationship of antigen dose, serum neutralizing antibody response and protection from challenge. Vaccine. 10:1992;699-706.
50. Periolo O. H., Seki C., Grigera P. R., Robiolo B., Fernandez G., Maradei E., D' Aloia R., La Torre J. L. Large-scale use of liquid-phase blocking sandwich ELISA for the evaluation of protective immunity against aphthovirus in cattle vaccinated with oil-adjuvanted vaccines in Argentina. Vaccine. 11:1993;754-760.
51. Pfaff E., Thiel H. J., Beck E., Strohmaier K., Schaller H. Analysis of neutralizing epitopes on foot-and-mouth disease virus. J. Virol. 62:1988;2033-2040.
52. Piirainen L., Roivainen M., Litmanen L., Eskola J., Coen Beuvery E., Hovi T. Immunogenicity of a pilot inactivated poliovirus vaccine with trypsin-treated type 3-component. Vaccine. 15:1997;237-243.
53. Pullen L. Routine care and management of guinea pigs in FMD vaccine testing. J. Inst. Anim. Tech. 32:1980;13-20.
54. Roivainen M., Hovi T. Intestinal trypsin can significantly modify antigenic properties of polioviruses: Implications for the use of inactivated poliovirus vaccine. J. Virol. 61:1987;3749-3753.
55. Roivainen M., Montagnon B., Chalumeau H., Murray M., Wimmer E., Hovi T. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice. J. Virol. 64:1990;559-562.
56. Roivainen M., Piirainen L., Hovi T. Persistence and class-specificity of neutralizing antibody response induced by trypsin-cleaved type 3 poliovirus in mice. Vaccine. 11:1993;713-717.
57. Roos R. P., Stein S., Routbort M., Senkowski A., Bodwell T., Wollmann R. Theiler's murine encephalomyelitis virus neutralisation escape mutants have a change in disease phenotype. J. Virol. 63:1989;4469-4473.
58. Rweyemamu M. Antigenic variation in foot-and-mouth disease: Studies based on the virus neutralisation reaction. J. Biol. Standard. 12:1984;323-337.
59. Ryman K. D., Xie H., Ledger T. N., Campbell G. A., Barrett A. D. T. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology. 230:1997;376-380.
60. Saiz J. C., Gonzalez M. J., Borca M. V., Sobrino F., Moore D. M. Identification of neutralising antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralisation-resistant variants. J. Virol. 65:1991;2518-2524.
61. Samuel A. R., Knowles N. J., Samuel G. D., Crowther J. R. Evaluation of a trapping ELISA for the differentiation of foot-and-mouth disease virus strains using monoclonal antibodies. Biologicals. 19:1991;299-310.
62. Schmaljohn A. L., Johnson E. D., Dalrymple J. M., Cole G. A. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature. 297:1982;70-72.
63. Spouge J. L. Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates. Proc. Natl. Acad. Sci. USA. 89:1992;7581-7585.
64. Steward M. W., Stanley C. M., Dimarchi R., Mulcahy G., Doel T. R. High-affinity antibody induced by immunization with a synthetic peptide is associated with protection of cattle against foot-and-mouth disease. Immunology. 72:1991;99-103.
65. Taylor G., Stott E. J., Bew M., Fernie B. F., Cote P. J., Collins A. P., Hughes M., Jebbett J. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology. 52:1984;137-146.
66. Thomas A. A. M., Woortmeijer R. J., Puijk W., Barteling S. J. Antigenic sites on foot-and-mouth disease virus A10. J. Virol. 62:1988;2782-2789.
67. Thevasagayam J. A., Mertens P. P. C., Burroughs J. N., Anderson J. Competitive ELISA for the detection of antibodies against epizootic haemorrhagic disease of deer virus. J. Virol. Methods. 55:1995;417-425.
68. Van Houten N., Bouchard P. E., Moraska A., Huber S. A. Selection of an attenuated coxsackievirus B3 variant, using a monoclonal antibody reactive to myocyte antigen. J. Virol. 65:1991;1286-1290.
69. Van Maanen C., Terpstra C. Comparison of a liquid-phase blocking sandwich ELISA and a serum neutralisation test to evaluate immunity in potency tests of foot-and-mouth disease vaccines. J. Immunol. Methods. 124:1989;111-119.
70. Virgin H. W., Bassel-Duby R., Fields B. N., Tyler K. L. Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J. Virol. 62:1988;4594-4604.
71. Wimmer E., Jameson B. A., Emini E. A. Poliovirus antigenic sites and vaccines. Nature. 308:1984;19.
72. Zurbriggen A., Fujinami R. S. A neutralization-resistant Theiler's virus variant produces an altered disease pattern in the mouse central nervous system. J. Virol. 63:1989;1505-1513.